All In Biotech

Drug Trial Radar · NCT03020992

A Study to Assess the Effects of Certolizumab Pegol on the Reduction of Anterior Uveitis (AU) Flares in Axial Spondyloarthritis Subjects With a Documented History of AU

Multicenter, Open-Label Study to Assess the Effects of Certolizumab Pegol on the Reduction of Anterior Uveitis Flares in Axial Spondyloarthritis Subjects With a History of Anterior Uveitis (C-VIEW)

Last checked: Nov 20, 2026Latest source record: Jun 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

89

Actual

Start

Dec 21, 2016

Primary completion

Dec 4, 2019

Study completion Jan 23, 2020

Sponsor

Lead sponsor
UCB Biopharma SRLUCB
Sponsor type
Industry
First posted
Jan 13, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study is to demonstrate the effect of Certolizumab Pegol (CZP) treatment on the reduction of Anterior Uveitis (AU) flares in subjects with active axial Spondyloarthritis (axSpA) and a documented history of AU.

Conditions

  • Axial Spondyloarthritis (axSpA)
  • Anterior Uveitis (AU)

Interventions

  • Certolizumab PegolDrug

    * pharmaceutical form: solution for infusion in prefilled syringe * concentration: 200 mg/mL * route of administration: subcutaneous

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Distinct Episodes of Anterior Uveitis (AU) Flares During the Treatment PeriodTime frame: During the pre-study period and during the Treatment Period up to 96 weeks

Locations

23 sites in 5 countries. Site status is shown where the registry gives one.

  • As0007 101

    Brno, Czechia

  • As0007 103

    Brno, Czechia

  • As0007 107

    Brno, Czechia

  • As0007 108

    Ostrava, Czechia

  • As0007 109

    Pardubice, Czechia

  • As0007 102

    Prague, Czechia

  • As0007 105

    Prague, Czechia

  • As0007 301

    Freiburg im Breisgau, Germany

  • As0007 302

    München, Germany

  • As0007 303

    Münster, Germany

  • As0007 401

    Amsterdam, Netherlands

  • As0007 506

    Bialystok, Poland

  • As0007 510

    Lublin, Poland

  • As0007 509

    Poznan, Poland

  • As0007 511

    Poznan, Poland

  • As0007 502

    Torun, Poland

  • As0007 501

    Warsaw, Poland

  • As0007 505

    Warsaw, Poland

  • As0007 504

    Wroclaw, Poland

  • As0007 507

    Wroclaw, Poland

  • As0007 508

    Wroclaw, Poland

  • As0007 604

    Barcelona, Spain

  • As0007 601

    Córdoba, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.